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Abstract
Since the discovery of the hepatitis B virus (HBV) by Blumberg et al., nearly half a
century ago, the subsequent development of a vaccine, understanding of the patho‐
genesis, and the advent of antiviral drugs, the prevalence of chronic hepatitis B has
decreased from approximately 5% to 3.61% of the worldwide population. Despite this
improvement, approximately 248 million individuals are still infected with the virus.
Effective treatment of chronic hepatitis B is extremely important as a positive correla‐
tion has been observed between baseline viral load and the risk for the development
of hepatocellular carcinoma (HCC). While there have been significant advancements
in the management of hepatitis B virus with available nucleos(t)ide analogues, there
remains much work to be done to prevent HCC. The molecular mechanism and the
subsequent carcinogenesis and progression of chronic HBV carriers to HCC remain in
large part poorly understood. While current treatment with nucleos(t)ide analogues has
succeeded in maintaining undetectable viral levels in patients with chronic hepatitis B,
eradication of the virus has not been possible, and there remains the risk of develop‐
ment of HCC. Therefore, more effective treatment regimens aiming for HBV cure are
urgently needed. With multiple new therapies in the pipeline, the future of treating
hepatitis B is an exciting and developing one, and hopefully, it will soon become a
disease of the past.
Keywords: hepatitis B, hepatocellular carcinoma, anti‐HBV drugs, nucleos(t)ide
analogues, HBV cure, HBV therapy

1. Introduction
In the past 50 years, since the discovery of the hepatitis B virus [1], the development of a
vaccine, understanding of the pathogenesis, and the advent of antiviral drugs, the preva‐
lence of chronic hepatitis B has decreased from approximately 5% to 3.61% of the worldwide
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population [2]. Nevertheless, hepatitis B remains a common and frequently encountered con‐
dition, affecting approximately 248 million individuals in the world.
The vast majority of individuals with chronic hepatitis B are located in Africa and Eastern
Asia. In the United States, over 2 million Americans are afflicted and the majority (1.5 mil‐
lion) are immigrants from foreign countries [3, 4]. Effective treatment of chronic hepatitis
B remains of extremely high importance, as patients who have been found to have higher
baseline viral loads have been shown to have increased rates of hepatocellular carcinoma
(HCC) [5]. As the treatment landscape of hepatitis B has shifted from earlier regimens of
interferon and lamivudine to newer agents, namely tenofovir and entecavir, there remains
much work to be done to reduce viral loads in patients and prevent long‐term sequelae of
cirrhosis and HCC. This chapter will discuss the natural history and potential carcinogenesis
of hepatitis B virus, and will discuss current and possible future treatments, and the hope
for an eventual cure.

2. Natural history of hepatitis B virus
In contrast to many known pathogens, hepatitis B virus (HBV) is not directly cytopathic
to hepatocytes. Although not completely understood, the injury to the liver cells is in part
through a host immune mechanism. Replicating HBV in hepatocytes produces HBsAg par‐
ticles and virions which are taken up by the antigen presenting cells. The viral proteins are
degraded to peptides, which are presented on the cell surface bound to MHC class I or II
molecules. MHC class I molecules are recognized by CD8 T cells and MHC II by CD4 T cells.
Virus‐specific CD8+ cytotoxic T cells, with help from CD4+ T cells, recognize viral antigens
presented on MHC class I chains on infected hepatocytes. This recognition reaction can lead
to either direct lysis of the infected hepatocyte or the release of interferon‐γ and TNF‐a,
which can down‐regulate viral replication in surrounding hepatocytes without direct cell
killing [6].
In order to further discuss advancements in the understanding and treatment of HBV, it is
important first to review the natural history of the disease. The cycle of chronic HBV infection
primarily consists of five phases as shown in Figure 1 [7, 8].
In the initial infection phase, or so‐called immune tolerant phase, patients have very minimal
inflammation. The hallmark of this phase is that these patients are found to be positive for
HBeAg with high viral loads, typically >20,000 IU/mL (> 105 copies/mL) [9]. Conversely, they
have normal aminotransferase (ALT) levels, and near‐normal liver parenchyma on biopsy
[10]. This “immune tolerant” phase is relatively short when HBV is acquired in adulthood,
but can be sustained for much longer periods of time with infections acquired at birth or in
early childhood [11, 12]. The risk of progressing to the chronic carrier state is significantly
higher in infections acquired at a younger age, including up to a 90% risk when infected
perinatally, as compared to a less than 1% risk of progression when acquired as an adult
[13, 14].
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Figure 1. Five phases of chronic hepatitis B *. * Adapted from Tong et al. (7) and modified by Halegoua‐DeMarzio and Hann (8).

Following the “immune tolerant” phase, patients progress into the “immune clearance” phase,
which again consists of high viral loads and a persistently positive HBeAg. However, at this
point patients begin experiencing increased inflammation, with elevated ALT levels, and
potential hepatic decompensation [15, 16]. It is at this point when the viral DNA levels of
HBV begin to decline, as does the presence of HBeAg. This is in large part due to the activated
T‐cell immune response, and subsequent destruction of infected hepatocytes [6]. An outcome
of the immune clearance phase is HBeAg seroconversion, which has been found to be critical
in predicting progression to cirrhosis and HCC.
Following HBeAg seroconversion, patients typically enter an “inactive carrier” phase, where
HBeAg becomes undetectable, and HBe antibodies (anti‐HBe) appear [17]. Typically the
patient's viral load is low or undetectable and ALT returns to normal. Biopsy at this time will
show minimal fibrosis and mild hepatitis. If the patient had experienced severe liver injury
during the “immune clearance” phase, cirrhosis can also be present [17].
During the “reactivation phase”, patients who were previously infected with HBV again have
a detectable viral load, elevated ALT, and inflammation seen on biopsy [18]. In contrast to the
“immune tolerant” phase, however, these patients do not have HBeAg positivity, but do have
positive anti‐HBe. As a result, this phase is known as the “HBeAg negative chronic hepatitis B”
phase. As with the “immune clearance” phase, these patients can exhibit marked inflammation
and hepatocyte destruction, and can experience hepatic decompensation during this phase.
The final phase of HBV infection is known as the “remission” or “inactive” phase, in which
HBsAg may become negative, but anti‐HBe and anti‐HBc remain positive. Transaminases are
normal at this time, and HBV viral loads are very low or undetectable.
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It is important to remember that once patients are infected, they remain positive for anti‐HBc
IgG throughout even after they lose HBsAg and after they acquire anti‐HBs. Also, anti‐HBe
may often remain detectable.
Furthermore, as part of the infection of HBV into human hepatocytes, HBV DNA converts
itself into a covalently closed circular DNA, known as cccDNA, inside the hepatocyte nucleus
[19]. This cccDNA serves as a template for transcription of HBV viral mRNAs, which translate
and produce HBV proteins as well as provide a template for HBV DNA synthesis [20]. Thus,
although a patient's viral load may be undetectable and HBsAg may become negative, the
patient is not cured of HBV, as cccDNA will remain within hepatocytes.

3. Current treatments for chronic hepatitis B
Anti‐HBV treatment drugs have made significant progress in improving the health and lifes‐
pan of patients with HBV. Beginning with interferon in 1991, therapies have become more
targeted with lower resistance profiles and more tolerable side effects. The ultimate goal of
hepatitis B treatment is to achieve remission, i.e., sustained suppression of viral replication.
This, in turn, will lead to prevention of progression to cirrhosis and/or HCC. Several studies
have demonstrated the reduction of HCC development with antiviral drugs [21–26].
Currently there are six approved treatments for HBV. The details of drugs and efficacy are
shown in Table 1.
Pegylated interferon alpha‐2a. The first treatment approved for HBV in 1991, pegylated
interferon alpha‐2a, or peg‐IFN α‐2a, is an immunomodulator, which also displays a weak
effect against the virus itself [27]. It is administered as an injection, which patients receive
weekly for a total treatment of 48 weeks. It has been shown to produce HBeAg seroconver‐
sion in 27% of patients, and 25% of patients develop an undetectable HBV DNA load [28]. It
has been shown to have the best response for those individuals with genotype A with either
ALT > 2x ULN or low HBV DNA, and for genotypes B and C with ALT > 2x ULN and low
HBV DNA [29]. Although an effective treatment in the past, peg‐IFN α‐2a is a small percent‐
age of current HBV treatments in the US [30]. Much of this is likely due to the requirement of
an injection weekly, a large percentage of patients who fail to respond, and a significant side
effect profile.
Lamivudine. The first nucleoside analogue approved for treatment of HBV, lamivudine
(LMV) is a reverse transcriptase inhibitor. Functioning as a nucleoside analogue, it inhibits
DNA synthesis of HBV. The treatment is extended across 1 year, and has been associated with
a seroconversion rate of 16–18% at 1 year, and increases up to nearly 50% at 4 years [31, 32]. It
is the least expensive of the nucleotide/nucleoside analogues, and is safe to use in pregnancy,
which is one of its most common uses in current times. LMV has also been shown to reduce
the rate of development of both fibrosis and HCC [33]. The most significant evidence of the
effectiveness of LMV was shown in a randomized, controlled trial by Liaw et al., comparing
LMV versus placebo in patients with chronic hepatitis B and high serum levels of HBV DNA
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* Adapted from Halegoua‐De Marzio and Hann (8).
Table 1. Treatment options of chronic hepatitis B*.

[33]. The primary endpoint was progression of liver disease identified as either an increase in
Child‐Pugh score, bleeding from esophageal varices, or development of HCC. The study was
discontinued early given that it demonstrated such a clear benefit of LMV compared to pla‐
cebo [33]. Despite the success that has been shown with LMV, its use is limited, mainly due to
the high incidence of resistance, especially compared with newer nucleotide/nucleoside ana‐
logues [34]. In one study, however, much lower resistance was observed if the baseline HBV
DNA was < 106 copies/mL [35], and there has been an extensive review as to the discrepancies
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of LMV resistance among the multiple studies regarding the incidence of LMV resistance [36].
LMV also reduced vertical HBV transmission from highly viremic mothers to their newborns
[37]. Currently, the use of oral antiviral agents during the first and second trimesters of preg‐
nancy is not recommended.
Adefovir dipivoxil. The first nucleotide analogue, adefovir dipivoxil (ADV), was approved
by the FDA for use in 2002. Similar to LMV in its mechanism of action, ADV functions as a
reverse transcriptase inhibitor. As compared with LMV, however, ADV had both an increased
antiviral potency, and an intrinsic stereoscopic structure that prevents emergence of viral
resistance. HBe seroconversion was achieved in 12% of patients after 1 year of therapy with
ADV, and a 53% rate of histological improvements in patients who were positive for HBeAg
[38]. Of the patients who did seroconvert, it was found to be sustained in 91% of these patients
[39]. Like LMV, however, prolonged use is associated with an increase in resistance, pro‐
gressing from 3% at 2 years to 29% at 5 years [40]. Due to this, in addition to associated renal
toxicity, the use of ADV has become increasingly rare with the development of newer, more
effective therapies.
Entecavir. The second nucleoside analogue approved for treatment of chronic HBV, entecavir
(ETV), was approved by the FDA for treatment in 2005. It has been shown to be superior at
reducing HBV DNA levels, as compared with LMV [41]. In a phase 3 study comparing ETV
to LMV after 1 year of treatment, patients were found to have improved virological response
with HBV DNA < 400 copies/mL (67% vs 36%), improvement on histologic examination (72%
vs 62%), and improvement in aminotransferases, namely ALT (78% returned to normal as
compared to 70%) [41]. In longer term studies, up to 96% of patients had improvement in
histologic examination, and improvement in fibrosis score after 6 years [42]. Improvements
were even found in patients with cirrhosis. Entecavir also was shown to keep HBeAg‐positive
patients with HBV DNA levels below 300 copies/mL in 94% of patients at 5 years [43]. It has
been shown to cause viral suppression quicker than ADV, and has been shown to significantly
decrease the incidence of HCC in chronic HBV patients, with a 3.7% incidence in the ETV
group as compared with 13.7% in the untreated group [23]. One of the most important fea‐
tures of entecavir, and a reason why it remains one of the two recommended treatments for
chronic HBV today, is that it has a high genetic barrier and a very low incidence of resistance.
The cumulative incidence of resistance after 6 years has been found to be 1.2% in nucleoside‐
naïve patients [44].
Telbivudine. Another nucleoside analogue similar in structure to LMV, telbivudine (TLV) was
approved by the FDA for treatment of chronic HBV in 2006. In HBeAg‐positive patients, the
seroconversion with TLV was found to be 22% at 1 year and 30% at 2 years [45, 46]. Viral sup‐
pression to less than 300 copies of DNA/mL was found to be 60% after 1 year of TLV therapy,
and 56% after two years of therapy [45, 46]. Unfortunately, although TLV was shown to have
promising effects and to have a higher barrier to resistance than LMV, resistance has been
found to be as high as 21.6% in HBeAg‐positive patients, and 8.6% in HBeAg‐negative patients
[47]. Because of this, TLV currently is not a recommended first‐line treatment. However, TLV
is shown to be highly effective for those with low baseline HBV DNA and achieves undetect‐
able HBV DNA at week 24. Therefore, TLV is highly effective for patients with the above
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characteristics [48]. Furthermore, recent studies report the renoprotective effect of TLV, its
role in preventing ADV‐induced nephrotoxicity, and increased GFR improvement of renal
function in liver transplant patients and in patients with compensated or decompensated
HBV‐related liver diseases [49–52]. The rate of vertical transmission was reduced when tel‐
bivudine was given to mothers with high viral loads during the third trimester of pregnancy
[53]. Currently, the use of oral antiviral agents during the first and second trimesters of preg‐
nancy is not recommended.
Tenofovir. The most recent nucleotide analogue, tenofovir disoproxil fumarate (TDF), was
approved by the FDA for treatment of patients with chronic hepatitis B in 2008. Structurally
similar but a more potent drug than ADV, TDF has been shown to produce more viral
suppression in HBeAg‐positive patients, with 76% of patients achieving viral loads < 400
copies/mL as compared with 13% of patients treated with ADV after 48 weeks of treatment
[54]. ALT normalization, histologic improvement, and HBsAg loss were all also found to
be significantly increased in patients treated with TDF as compared with ADV [54]. Data
have shown an excellent continued response, with a 7‐year viral suppression (HBV DNA
levels < both 69 IU/mL and 29 IU/mL) of greater than 99% in both HBeAg‐negative and
HBeAg‐positive patients [55]. In addition to its effectiveness, TDF has also been shown to
have an extremely favorable resistance profile [56]. Due to the effectiveness and the virtual
absence of resistance, TDF has been recommended as a first‐line treatment in patients with
chronic hepatitis B.
Several currently used guidelines are shown in Table 2.
Since the majority of chronic hepatitis B patients in the United States are immigrants form
endemic countries, especially from Asia, where infection takes place commonly at birth or in
early childhood, Asian‐American algorithm is frequently used for treatment for this majority
of HBV patients. These guidelines are as follows [7]:
1. For HBeAg (+) or (-) patient with chronic HBV with DNA > 104 copies/mL (> 2000 IU/mL)
and ALT > ULN, treatment should be started with a first‐line agent (ETV or TDF).
2. For cirrhotic patients with detectable HBV DNA, treatment should be started with ETV or
TDF.
3. In HBeAg (-) patients with HBV DNA > 104 copies/mL (> 2000 IU/mL) and normal ALT, a
liver biopsy is recommended. If not available, further stratification for risk factors (albu‐
min ≤ 3.5 g/dL or platelets ≤ 130,000/μL, HCC first degree relative, age ≥ 40, male gender,
ALT > 30 U/L for male and 19 U/L for female) should be conducted prior to treatment.
4. Monitoring treatment: Test for serum ALT every 3 months. Measure HBV DNA every 3
months until negative, then every 3–6 months. Measure HBeAg every 6 months until
negative, then test for anti‐HBe.
5. After seroconversion from HBeAg‐positive to anti‐HBe, test for HBsAg every 12 months.
In HBeAg (-) patients, test for HBsAg every 12 months after sustained suppression of
HBV DNA.
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*EASL (European Association for the Study for the Liver) (72),
US Algorithm (73)
APASL (Asian Pacific Association of the Study of the Liver (74)
AASLD (American Association of the Study of Liver Diseases) (75)
Asian American Algorithm (7)
ULN = Upper limit of normal; NS = Not stated).
* UNL: 30 IU/mL for men, 19 IU/mL for women
2000 IU/mL = 104copies/mL
20,000 IU/mL=105copies/mL
Table 2. Current treatments for hepatitis B in chronic hepatitis, as recommended by different guidelines (ref. 7, 69–72).

6. Monitoring of resistance: Viral breakthrough with confirmation of single drug resistance
requires switching to another first‐line oral antiviral agent.
7. Surveillance for HCC with Alpha‐fetoprotein (AFP) and abdominal ultrasound should be
performed every 6 months in HBsAg‐positive patients with chronic hepatitis, cirrhosis,
and for patients with a family history of HCC.
8. With regard to stopping treatment, for HBeAg (+) patients, following HBeAg seroconver‐
sion, continue consolidation for 1–2 years before stopping therapy. However, the relapse
rate is high, and longer consolidation therapy may be needed. For HBeAg (-) patients,
antiviral therapy should be indefinite therapy until HBsAg seroconversion.
Before the antiviral drugs became available, 25–40% of HBV‐infected individuals used to
progress from chronic hepatitis to cirrhosis and eventually to HCC as shown in Table 3
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Table 3. Natural history of chronic hepatitis B infection.

Figure 2. Higher baseline viral loads are associated with increased rate of HCC. *From Chen, et al. (5).

In their 13‐year follow‐up study of HBV‐infected carriers, Chen et al. have noted that higher
baseline viral loads were associated with an increased rate of HCC [5] (Figure 2).
During the last 10 years, several studies have demonstrated that antiviral treatment signifi‐
cantly reduced the incidence of HCC [21–26]. However, all these treatment modalities are
to suppress HBV replication. They do not fully eradicate the virus. The inability to eradi‐
cate HBV still leaves infected individuals at the risk for HCC. Current anti‐HBV treatment
can achieve “functional cure” but not “complete cure”, the terminology as coined by Zeisel
et al. [19]. (Table 4).
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*Ab, antibodies; cccDNA, covalently closed circular DNA
Adapted and edited from Zeisel et al. (19)
Table 4. Definitions of HBV Cure.

4. Hepatocarcinogenesis
The pathogenesis for HBV‐related HCC is not fully understood, but is likely multifactorial.
HBV DNA level is a known factor, and the presence of HBV DNA has been shown to have
a linear relationship to the development of HCC [5]. A high viral load leads to a persistent
immune response against hepatocytes, with persistent inflammation, regeneration, and fibro‐
sis. This up‐regulated state of inflammation can in turn predispose to a malignant transforma‐
tion [57]. Several studies have also suggested that the integration of HBV DNA into the host
DNA can lead to chromosomal instability and eventual gene rearrangement. These rearrange‐
ments can, in effect, lead to deregulation and instability of gene expression, subsequently
leading to oncogenesis [58–60].
The association with chronic HBV and HCC has been described as early as the 1970s. The land‐
mark cohort study by Beasley et al. in 1981, which studied over 22,000 men in Taiwan, showed
a significant association between chronic HBV carriers and the development of HCC. In this
study, the relative risk of development of HCC in men with chronic HBV was determined to
be 63 times higher as compared with uninfected individuals [61]. This study also designated
the HBV vaccine (plasma vaccine by Blumberg and Millman followed by the recombinant
vaccine) as the first “Cancer Vaccine” by the World Health Organization. The increased risk of
HCC in patients with HBV has repeatedly been confirmed with smaller, more recent studies.
Although HBsAg seroconversion and viral suppression are typically associated with protec‐
tion against HCC, patients who have cleared their viral load have still been found to acquire
HCC. This is likely due to the continued presence of cccDNA, in a mechanism that is not well
understood. Studies have also shown that HCC development is better associated with patients
who have had active HBV infection for longer time periods, including patients who were
infected at younger ages. Thus, it is thought that HCC progression is likely a result of HBV
replication itself and subsequent liver injuries that follow [62]. It also raises the point that in
individuals infected earlier, carcinogenic processes may have already been in play prior to the
halt of viral replication later in life, and the ability of HBV to integrate into the infected host's
hepatocyte genome is one of the most important direct pro‐oncogenic properties.
In addition to chronic HBV carrier status, other risk factors have been identified which pre‐
dispose patients with hepatitis B to HCC. These factors include co‐infection with hepatitis
C (HCV), a family history of prior HCC, concurrent alcohol use, and a predominance of
genotype C [63–66]. Additionally, the presence of core promoter mutations, the most com‐
mon of which is the HBx protein, a potent activator of multiple genes, including oncogenes,
has been discovered [67].
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5. Future treatments
Most current guidelines recommend against HBV treatment of patients in the immune toler‐
ant phase (Table 2). However, recent reports have indicated evidence that immune reactivity
is in fact present in patients during this immune tolerant stage [68–70]. There is a growing
opinion that to prevent HCC, we should consider earlier treatment of chronic hepatitis B as
lucidly reasoned by Zoulim and Mason [71]. Given the emergence of HCC even in patients
who had become seronegative, these guidelines should be readdressed in order to treat
patients starting at a younger age, in order to prevent progression of disease and the develop‐
ment of HCC, as viral suppression alone has not proven effective for the absolute prevention
of HCC. Additionally, the required long‐term therapy imposes not only financial burden but
may also put patients at risk for potential drug resistance and unknown toxicity.
Along with nucleoside/nucleotide analogues, treatment may need to include targeting the
cccDNA and inhibiting viral entry into the newly formed hepatocytes. This may be accom‐
plished via a T‐cell vaccine which specifically targets HBV, enhancing innate immunity
with toll‐like receptor agonist. Several compounds have been identified which have the

*cccDNA, covalently closed circular DNA; DAA, direct‐acting antiviral; FDA, US Food and Drug Administration; HCC,
hepatocellular carcinoma; HTA, host‐targeting agent; IFN, interferon; LTβR, lymphotoxin‐β receptor; NTCP, sodium
taurocholate co‐transporting polypeptideAdapted and edited from Zeisel et al. (19)
Table 5. Emerging drugs against HBV.
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potential for eradicating the virus. The clinical trials are in progress at different phases
to further investigate these compounds [19]. Among these are direct‐acting antagonists
against the HBV capsid, against the HBV cccDNA, and against the HBV RNA. While the
targets enhancing the innate immunity are mainly in the preclinical phase, they pose excit‐
ing possibilities for the future of HBV treatment. The potential drugs in the pipelines are
shown below [19] (Table 5).

6. Conclusion
While there have been significant advancements in the understanding and management
of hepatitis B virus, there remains much to be learned. The molecular mechanism and the
subsequent carcinogenesis and progression of chronic HBV carriers to HCC remain in large
part poorly understood. While significant improvements in treatment of HBV continue to be
made, research toward HBV complete cure and the treatment landscape now is much differ‐
ent than it was at the end of the twentieth century. The development of nucleotide and nucleo‐
side analogues, particularly entecavir and tenofovir, has significantly improved the ability of
chronic HBV carriers to remain with undetectable viral levels. There remains, however, the
possibility of development of HCC, in part likely in the early stages of infection, as well as the
viral incorporation into hepatocyte DNA. Therefore, more effective treatment regimens need
to be developed, and the prospect of treating individuals at earlier stages of HBV should be
addressed. With multiple new therapies in the pipeline, the future of treating hepatitis B is an
exciting and developing one, and hopefully, it will soon become a disease of the past.

Disclosures:
AD, no conflict, HWH, receives research grants from Bristol Myers‐Squibb and Gilead Sciences.

Author details
Andrew Dargan2 and Hie‐Won Hann1, 2*
*Address all correspondence to: hie‐won.hann@jefferson.edu
1 Liver Disease Prevention Center, Department of Medicine, Thomas Jefferson University
Hospital, Philadelphia, PA, USA
2 Division of Gastroenterology and Hepatology, Department of Medicine, Thomas Jefferson
University Hospital, Philadelphia, PA, USA

References
[1] Blumberg BS, Alter HJ, Visnich S. A “new” antigen in leukemia sera. JAMA. 1965;
191:541–546.

Treatment of Chronic Hepatitis B: An Update and Prospect for Cure
http://dx.doi.org/10.5772/66724

[2] Schweitzer A, Horn J, Mikolajczyk RT, Krause G, Ott JJ. Estimations of worldwide
prevalence of chronic hepatitis B virus infection: a systematic review of data published
between 1965 and 2013. Lancet. 2015; 386:1546–1555.
[3] Cohen C, Evans AA, London WT, Block J, Conti M, Block T. Underestimation of chronic
hepatitis virus infection in the United States of America. J Viral Hepatitis. 2008; 15:12–13.
[4] Kim WR. Epidemiology of hepatitis B in the United States. Hepatology. 2009; 49:S28–S34.
[5] Chen C‐J, Yang H‐I, Su J, Jen C‐L, You S‐L, Lu S‐N, Huang GT, Iloeje UH. Risk of hepa‐
tocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level.
JAMA. 2006; 295:65–73.
[6] Ganem D, Prince AM. Hepatitis B virus infection, natural history and clinical conse‐
quences. N Engl J Med. 2004; 350:1118–1129.
[7] Tong MJ, Pan CQ, Hann HW, Kowdley KV, Han SH, Min AD, Leduc TS. The manage‐
ment of chronic hepatitis B in Asian Americans. Dig Dis Sci. 2011; 56:3143–3162.
[8] Halegoua‐DeMarzio D, Hann HW. Prevention of hepatocellular carcinoma and its recur‐
rence with anti‐hepatitis B viral therapy. Minerva Gastroenterol Dietol. 2014; 60:191–200.
[9] Croagh CMN, Lubel JS. Natural history of chronic hepatitis B: phases in a complex rela‐
tionship. World J Gastroenterol. 2014; 20:10395–10404.
[10] Chu CM, Karayiannis P, Fowler MJ, Monjardino J, Liaw YF, Thomas HC. Natural his‐
tory of chronic hepatitis B virus infection in Taiwan: studies of hepatitis B virus DNA in
serum. Hepatology. 1985; 5:431–434.
[11] Fattovich G, Bortolotti F, Donato F. Natural history of chronic hepatitis B: special empha‐
sis on disease progression and prognostic factors. J Hepatol. 2008; 48:335–352.
[12] Villa E, Fattovich G, Mauro A, Pasino M. Natural history of chronic HBV infection: spe‐
cial emphasis on the prognostic implications of the inactive carrier state versus chronic
hepatitis. Dig Liver Dis [Internet]. 2011; 43(Suppl 1):S8–S14.
[13] Beasley RP, Hwang LY, Lin CC, Leu ML, Stevens CE, Szmuness W, Chen KP. Incidence
of hepatitis B virus infections in preschool children in Taiwan. J Infect Dis. 1982;
146:198–204.
[14] Beasley RP, Trepo C, Stevens CE, Szmuness W. The e antigen and vertical transmission
of hepatitis B surface antigen. Am J Epidemiol. 1977; 105:94–98.
[15] Liaw YF, Tai DI, Chu CM, Chen TJ. The development of cirrhosis in patients with chronic
type B hepatitis: a prospective study. Hepatology. 1988; 8:493–496.
[16] McMahon BJ, Holck P, Bulkow L, Snowball M. Serologic and clinical outcomes of
1536 Alaska natives chronically infected with hepatitis B virus. Ann Intern Med. 2001;
135:759–768.
[17] Yim HJ, Lok AS‐F. Natural history of chronic hepatitis B virus infection: what we knew
in 1981 and what we know in 2005. Hepatology. 2006; 43(2 Suppl 1):S173–S181.

143

144

Advances in Treatment of Hepatitis C and B

[18] Hadziyannis SJ, Vassilopoulos D. Hepatitis B e antigen‐negative chronic hepatitis B.
Hepatology. 2001; 34:617–624.
[19] Zeisel MB, Lucifora J, Mason WS, Sureau C, Beck J, Levrero M, Kann M, Knolle PA,
Benkirane M, Durante D, Michel ML, Autran B, Cosset FL, Strick‐Marchand H, Trepo
C, Kao JH, Carrat F, Lacombe K, Schinazi RF, Barre‐Sinoussei F, Delfraissy JF, Zoulim
F. Towards an HBV cure: state‐of‐the‐art and unresolved questions‐report of the ANRS
workshop on HBV cure. Gut. 2015; 64:1314–1326.
[20] Summers J, Mason WS. Replication of the genome of a hepatitis B‐like virus by reverse
transcription of an RNA intermediate. Cell. 1982; 29:403–415.
[21] Liaw YF, Sung JJ, Chow WC, Farrell G, Lee CZ, Yuen H, et al. Lamivudine for patients
with chronic hepatitis B and advanced liver disease. N Engl J Med. 2004; 351:1521–1531.
[22] Eun JR, Lee HJ, Kim TN, Lee KS. Risk assessment for the development of hepatocel‐
lular carcinoma: according to on‐treatment viral response during long‐term lamivudine
therapy in hepatitis B virus‐related liver disease. J Hepatol. 2010; 53:118–125
[23] Hosaka T, Suzuki F, Kobayashi M, Seko Y, Kawamura Y, Sezaki H, Akuta N, Suzuki Y,
Saitoh S, Arase Y, Ikeda K, Kobayashi M, Kumada H. Long‐term entecavir treatment
reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection.
Hepatology. 2013; 58:98–107.
[24] Wong GL, Chan HL, Chan HY, Tse YK, Mark CW, Lee SK, Ip ZM, Lam AT, Iu JW, Leung
JM, Wong VW. Accuracy of risk scores for patients with chronic hepatitis B receiving
entecavir treatment. Gastroenterology. 2013; 144:933–944.
[25] Ahn J, Lim JK, Lee HM, Lok AS, Nguyen M, Pan CQ, Mannalithara A, Te H, Reddy
KR, Trinh H, Chu D, Tran T, Lau D, Leduc T‐S, Min A, Le LT, Bae H, Tran SV, Do
S, Hann HW, Wong C, Han S, Pillai A, Park JS, Tong M, Scaglione S, Woog J, Kim
WR. Lower observed hepatocellular carcinoma incidence in chronic hepatitis B patients
treated with entecavir: results of the ENUMERATE study. Am J Gastroenterol. 2016;
111:1297–1304.
[26] Kim WR, Loomba R, Berg T, Schall REA, Yee LJ, Dinh PV, et al. Impact of long‐term
tenofovir disoproxil fumarate on incidence of hepatocellular carcinoma in patients with
chronic hepatitis B. Cancer. 2015; 121:3631–3638
[27] Dianzani F. Biological basis for the clinical use of interferon. Gut. 1993; 34(2
Suppl):S74–S76.
[28] Lau GKK, Piratvisuth T, Luo KX, Marcellin P, Thongsawat S, Cooksley G, et al.
Peginterferon Alfa‐2a, lamivudine, and the combination for HBeAg‐positive chronic
hepatitis B. N Engl J Med. 2005; 352(26):2682–2695.
[29] Buster EHCJ, Hansen BE, Lau GKK, Piratvisuth T, Zeuzem S, Steyerberg EW, et al.
Factors that predict response of patients with hepatitis B e antigen‐positive chronic hep‐
atitis B to peginterferon‐alfa. Gastroenterology. 2009; 137:2002–2009.

Treatment of Chronic Hepatitis B: An Update and Prospect for Cure
http://dx.doi.org/10.5772/66724

[30] Zoulim F, Perrillo R. Hepatitis B: reflections on the current approach to antiviral therapy.
J Hepatol. 2008; 48:S2–S19.
[31] Dienstag JL, Schiff ER, Wright TL, Perrillo RP, Hann HW, Goodman Z, et al. Lamivudine
as initial treatment for chronic hepatitis B in the United States. N Engl J Med. 1999;
341:1256–1263.
[32] Chang TT, Lai CL, Chien RN, Guan R, Lim SG, Lee CM, et al. Four years of lamivudine
treatment in Chinese patients with chronic hepatitis B. J Gastroenterol Hepatol. 2004;
19:1276–1282.
[33] Liaw Y‐F, Sung JJY, Chow WC, Farrell G, Lee C‐Z, Yuen H, Tanwandee T, Tao QM, Shue
K, Keene ON, Dixon JS, Gray DE. Sabbat J. Lamivudine for patients with chronic hepati‐
tis B and advanced liver disease. N Engl J Med. 2004; 351:1521–1531.
[34] Lok ASF, Lai CL, Leung N, Yao GB, Cui ZY, Schiff ER, Dienstag JL, Heathcote EJ, Little
NR, Griffiths DA, Gardner SD, Castiglia M. Long‐term safety of lamivudine treatment in
patients with chronic hepatitis B. Gastroenterology. 2003; 125:1714–1722.
[35] Chae HB, Hann HW. Baseline HBV DNA level is the most important factor associated
with virologic breakthrough in chronic hepatitis B treated with lamivudine. World J
Gastroenterol. 2007; 13:4085–4090.
[36] Hann HW, Gregory VL. Dixon JS, Barker KF. A review of the one year incidence of resis‐
tance to lamivudine in the treatment of chronic hepatitis B. Hepatology Int. 2008; 2:440–456.
[37] Xu W‐M, Cui Y‐T, Wang L, Yang H, Liang ZQ, Li XM, Zhang SL, Qiao FY, Campbell F,
Chang CN, Gardner S, Atkins M. Lamivudine in late pregnancy to prevent perinatal
transmission of hepatitis B virus infection: a multicentre, randomized, double‐blind, pla‐
cebo‐controlled study. J Viral Hepat. 2009; 16:94–103.
[38] Marcellin P, Chang T‐T, Lim SG, Tong MJ, Sievert W, Shiffman ML, Jeffers L, Goodman
Z, Wulfsohn MS, Xiong S, Fry J, Brosgart CL. Adefovir dipivoxil for the treatment of
hepatitis B e antigen‐positive chronic hepatitis B. N Engl J Med. 2003; 348:808–816.
[39] Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, Chang T‐T, Kitis G, Rizzetto M, Marcellin
P, Lim SG, Goodman Z, Wulfsohn MS, Xiong S, Fry CL, Brosgart CL. Adefovir dipivoxil
for the treatment of hepatitis B e antigen‐negative chronic hepatitis B. N Engl J Med.
2003; 348:800–807.
[40] Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, Chang TT, Kitis G, Rizzetto M, Marcellin
P, Lim SG, Goodman Z, Ma J, Brosgart CL, Borroto‐Esoda K, Arterburn S, Chuc S. Long‐
term therapy with adefovir dipivoxil for HBeAg‐negative chronic hepatitis B for up to 5
years. Gastroenterology. 2006; 131:1743–1751.
[41] Chang TT, Gish RG, de Man R, Gadano A, Sollano J, Chao YC, Lok AS, Han KH,
Goodman Z, Zhu ZJ, Cross A, DeHertogh D, Wilber R, Colonno R, Apelian D. A com‐
parison of entecavir and lamivudine for HBeAg‐positive chronic hepatitis B. N Engl J
Med. 2006; 354:1001–1010.

145

146

Advances in Treatment of Hepatitis C and B

[42] Chang TT, Liaw YF, Wu SS, Schiff E, Han KH, Lai CL, Safasi R, Lee SS, Halota W,
Goodman Z, Chi YC, Zhang H, Hindes R, Iloeje S, Kreter B. Long‐term entecavir therapy
results in the reversal of fibrosis/cirrhosis and continued histological improvement in
patients with chronic hepatitis B. Hepatology. 2010; 52:886–893.
[43] Chang T‐T, Lai C‐L, Kew Yoon S, Lee SS, Coelho HSM, Carrilho FJ, Poordad F, Halota W,
Horsmans Y, Tsai N, Zhang H, Tenney DJ, Tamez R, Iloeje U. Entecavir treatment for up
to 5 years in patients with hepatitis B e antigen‐positive chronic hepatitis B. Hepatology.
2010; 51:422–430.
[44] Tenney DJ, Rose RE, Baldick CJ, Pokornowski KA, Eggers BJ, Fang J, Wichroski MJ,
Xu D, Yang J, Wilber RB, Colonno RJ. Long‐term monitoring shows hepatitis B virus
resistance to entecavir in nucleoside‐naive patients is rare through 5 years of therapy.
Hepatology. 2009; 49:1503–1514.
[45] Liaw YF, Gane E, Leung N, Zeuzem S, Wang Y, Lai CL, Heathcote EJ, Manns M, Bzowej
N, Niu J, Han SH, Hwang SG, Cakaloglu Y, Tong MJ, Papatheodoridis G, Chen Y, Brown
NA, Albanis E, Galil K, Naoumov NY. 2‐year GLOBE trial results: Telbivudine is superior
to lamivudine in patients with chronic hepatitis B. Gastroenterology. 2009; 136:486–495.
[46] Lai CL, Gane E, Liaw YF, Hsu CW, Thongsawat S, Wang Y, Chen Y, Heathcote EJ,
Rasenack J, Bzowej N, Naoumov NV, Di Bisceglie AM, Zeuzem S, Moon YM, Goodman
Z, Chao G, Constance BF, Brown NA. Telbivudine versus lamivudine in patients with
chronic hepatitis B. N Engl J Med. 2007; 357:2576–2588.
[47] Sonneveld MJ, Janssen HLA. Chronic hepatitis B: peginterferon or nucleos(t)ide ana‐
logues? Liver Int. 2011; 31(Suppl. 1):78–84.
[48] Hann HW. Telbivudine for the treatment of hepatitis B. Expert Opin Pharmacother.
2010; 11:2243–2249.
[49] Gane EJ, Deray G, Liaw Y‐F, Lim SG, Lai CL, Rasenack J, Wang Y, Papatheodoridisl G, Di
Bisceglie A, Bull M, Samuel D, Uddin A, Bosset S, Trylesinski A. Telbivudine improves
renal function in patients with chronic hepatitis B. Gastroenterology. 2014; 146:138–135.
[50] Lee M, Oh S, Lee HJ, Yeum TS, Lee JH, Yu SJ, Kim HY, Yoon JH, Lee HS, Kim YJ.
Telbivudine protects renal function in patients with chronic hepatitis B infection in con‐
junction with adefovir‐based combination therapy. J Viral Hepatol. 2014; 21:873–881.
[51] Li W, Zhang D. Influence of monotherapy with telbivudine or entecavir on renal func‐
tion in patients with chronic hepatitis B. Zhonghua Ganzangbing Zazhi Chin J Hepatol.
2015; 23:407–411.
[52] Perrella A, Lanza A, Pisaniello D, DiCostanzo G, Calise F, Cuomo O. Telbivudine pro‐
phylaxis for hepatitis B virus recurrence after liver transplantation improves renal func‐
tion. Transplant Proc. 2014. 2319–2321.
[53] Han G‐R, Cao M‐K, Zhao W, Jiang H‐X, Wang C‐M, Bai S‐F, et al. A prospective
and open‐label study for the efficacy and safety of telbivudine in pregnancy for the

Treatment of Chronic Hepatitis B: An Update and Prospect for Cure
http://dx.doi.org/10.5772/66724

prevention of perinatal transmission of hepatitis B virus infection. J Hepatol. 2011;
55:1215–1221.
[54] Marcellin P, Heathcote EJ, Buti M, Gane E, de Man R A, Krastev Z, Germanidis G, Lee
SS, Flisiak R, Kaita K, Manns M, Kotzev I, Tchernev K, Buggisch P, Weilert F, Kurdas
OO, Shiffman ML, Trinh H, Washington MK, Sorbek K, Anderson J, Snow‐Lampart A,
Mondou E, Quinn J, Rousseau F. Tenofovir disoproxil fumarate versus adefovir dipiv‐
oxil for chronic hepatitis B. N Engl J Med. 2008; 359:2442–2455.
[55] Buti M, Tsai N, Petersen J, Flisiak R, Gurel S, Krastev Z, Schall RA, Flaherty JF, Martins
EB, Charuworn P, Kitrinos KM. Seven‐year efficacy and safety of treatment with teno‐
fovir disoproxil fumarate for chronic hepatitis B virus infection. Dig Dis Sci. 2015;
60:1457–1464.
[56] Tsai N, Gane E, Weilert F, Buti M, Jacobson I, Washington MK, et al. Five years of treat‐
ment with tenofovir disoproxil fumarate (TDF) for chronic hepatitis B (CHB) infection
in lamivudine‐experienced patients is associated with sustained viral suppression and
histological improvement. Hepatol Int. 2012; 6:106.
[57] Chisari FV, Isogawa M, Wieland SF. Pathogenesis of hepatitis B virus infection. Pathol
Biol (Paris). 2010; 58:258–266.
[58] Bréchot C. Pathogenesis of hepatitis B virus‐related hepatocellular carcinoma: old and
new paradigms. Gastroenterology. 2004; 127(5 Suppl. 1):S56–S61.
[59] Fourel G, Trepo C, Bougueleret L, Henglein B, Ponzetto A, Tiollais P, et al. Frequent acti‐
vation of N‐myc genes by hepadnavirus insertion in woodchuck liver tumours. Nature.
1990; 347:294–298.
[60] Matsubara K, Tokino T. Integration of hepatitis B virus DNA and its implications for
hepatocarcinogenesis. Mol Biol Med. 1990; 7:243–260.
[61] Beasley RP, Lin C‐C, Hwang L‐Y, Chien C‐S. Hepatocellular carcinoma and hepatitis B
virus. Lancet. 1981; 318:1129–1133.
[62] Kremsdorf D, Soussan P, Paterlini‐Brechot P, Brechot C. Hepatitis B virus‐related hepa‐
tocellular carcinoma: paradigms for viral‐related human carcinogenesis. Oncogene.
2006; 25:3823–3833.
[63] Benvegnu L. Natural history of compensated viral cirrhosis: a prospective study on the
incidence and hierarchy of major complications. Gut. 2004; 53:744–749.
[64] Yu MW, Chang HC, Liaw YF, Lin SM, Lee SD, Liu CJ, et al. Familial risk of hepatocel‐
lular carcinoma among chronic hepatitis B carriers and their relatives. J Natl Cancer Inst.
2000; 92:1159–1164.
[65] Ohnishi K, Ilda SH, Iwama S, Goto N, Nomura F, Takahashi M, Mishima A, Kono K,
Kimura K, Musha H, Kotota K. The effect of chronic habitual alcohol intake on the devel‐
opment of liver cirrhosis and hepatocellular carcinoma: relation to hepatitis B surface
antigen carriage. Cancer. 1982; 49:672–677

147

148

Advances in Treatment of Hepatitis C and B

[66] Tsubota A, Arase Y, Ren F, Tanaka H, Ikeda K, Kumada H. Genotype may correlate with
liver carcinogenesis and tumor characteristics in cirrhotic patients infected with hepati‐
tis B virus subtype adw. J Med Virol. 2001; 65:257–265.
[67] Zheng Y, Li J, Ou J. Regulation of hepatitis B virus core promoter by transcription factors
HNF1 and HNF4 and the viral X protein. J Virol. 2004; 78:6908–6914.
[68] Bertoletti A, Kennedy PT. The immune tolerant phase of chronic HBV infection: new
perspectives on an old concept. Cell Mol Immunol. 2015; 12:258–263.
[69] Kennedy PT, Sandalova E, Jo J, et al. Preserved T‐cell function in children and young
adults with immune‐tolerant chronic hepatitis B. Gastroenterology. 2012; 143:637–645.
[70] Levy O. Innate immunity of the newborn: basic mechanisms and clinical correlates. Nat
Rev Immunol. 2007; 7:379–390.
[71] Zoulim F, Mason WS. Reasons to consider earlier treatment of chronic HBV infections.
Gut. 2012; 61:333–336.
[72] European Association for the Study of the Liver. EASL clinical practice guidelines: man‐
agement of chronic hepatitis B virus infection. J Hepatol. 2012; 57:167–185.
[73] Martin P, Lau DT‐Y. Nguyen MH, Janssen HLA, Dietrich DT, Peters MG, Jacobson IM.
Treatment algorithm for the management of chronic hepatitis B virus infection in the
United States: 2015 update. Clin Gastroenterol Hepatol. 2015; 13:2071–2087.
[74] Sarin SK, Kumar M, LauGK. Abbas Z, Chan HLY, Chen CJ, Chen DS, Chen HL, Chen PJ,
Chien RN, Dokmec AK, Gane E, Hou JL, Jafri W, Jia J, Kim JH, Lai CL, Lee HC, Lim SG,
Liu CJ, Locarnini S, Mahtab MAI, Mohamed R, Omata M, Park J, Piratvisuth T, Sharma
BC, Sollano J, Wang FS, Wei L, Yuen MF, Zheng SS, Kao JH. Asian‐Pacific clinical practice
guidelines on the management of hepatitis B: a 2015 update. Hepatol Int. 2016; 10:1–98.
[75] Terrault NA, Bzowej NH, Chang KM, Hwang JP, Jonas MM, Murad MH. AASLD guide‐
lines for treatment of chronic hepatitis B. Hepatology. 2016; 63(1):261–283.

